Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Israel Patients with cannabis licence can receive prescriptions at pharmacies ...
  • Kentucky - United States Doctors can start recommending medical cannabis to patients next month ...
  • Uruguay Presidential frontrunners unlikely to change cannabis legislation ...
  • Europe Agreement on EC make-up could include cannabis-conservative health commissioner ...
  • Ukraine New additions to list of prohibited psychotropic substances ...
  • Germany BfArM published medical cannabis import data for for Q3 2024 ...
  • Denmark Government plans to make medical cannabis scheme permanent ...
  • United States Senate committee releases Farm Bill draft ...
  • Luxembourg Medical cannabis patients to see restrictions in 2025 ...
  • Moldova Passed amendment allows for registered hemp varieties to be cultivated ...
  • Germany Cannabis legalisation debate takes place ahead of snap elections ...
  • Ireland Ruling parties disagree on proposal to decriminalise personal drug use ...
View all
News analysis

A ‘milestone’ for psychedelics as clinical trial begins in US with FDA’s blessing

Written by || 18th July 2022 || News analysis | Psychedelics | GeographiesNorth America United States

As the first federally approved psychedelics clinical trial begins in the US, there is broad but not total agreement among official bodies over legalising research into hallucinogenic substances.

The first Phase 1 study into psilocin and psilocybin to be approved by the US Food and Drug Administration (FDA) will examine the physiological and psychological effects of the mushroom-derived compounds when delivered orally and sublingually to healthy adults.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Login

Freddie Dawson

Senior news editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the CannIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.